
Zymeworks rose 9.8% from $23.90 to $26.24, behind the S&P 500's +13.3%. Its worst day was May 8 (−10.2%), and its low came Aug 3 at $21.81.
Nov 17, 2025 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.55 missed the $-0.33 estimate on $2.5M revenue (est. $20.9M).
+0.1% · S&P 500 +0.1%
Zymeworks shares fell 7.6%, while the S&P 500 fell 1.5%.
Story events cover the past 12 months · Times ET
−7.6% · S&P 500 −1.5%
EPS of $-0.59 missed the $-0.10 estimate on $2.4M revenue (est. $37.4M).
−10.2%, the year's worst day · S&P 500 +0.8%
Zymeworks shares rose 8.5%, while the S&P 500 rose 0.8%.
+8.5%, the year's best day · S&P 500 +0.8%
EPS of $-0.62 missed the $-0.40 estimate on $4.6M revenue (est. $18.9M).
+1.8% · S&P 500 +0.6%
Zymeworks shares rose 7.9%, while the S&P 500 rose 0.4%.
+7.9% · S&P 500 +0.4%
EPS of $2.28 beat the $2.23 estimate on $256.5M revenue (est. $226.7M); FY revenue guidance of $337.0M–$351.0M against the $297.6M consensus.
+2.1% · S&P 500 −0.4%
Where it ended: a close of $26.24 on Nov 13, 2026. Up next: Q4 2026 earnings on Mar 1, 2027 (EPS est. $-0.03, revenue est. $35.9M).
Nothing in the past 12 months.
All ZYME dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ZYME and SPY from Benzinga historical bars. Not investment advice.